Alzamend Neuro (ALZN) Cash from Operations (2020 - 2026)

Alzamend Neuro has disclosed Cash from Operations across 7 years of filings, most recently posting -$2.8 million for Q2 2026.

• In Q2 2026, Cash from Operations fell 306.17% year-over-year to -$2.8 million; the TTM figure through Apr 2026 stood at -$8.1 million (down 22.83% YoY), while the FY2026 annual figure was -$8.1 million, down 22.83% from the prior year.
• Cash from Operations came in at -$2.8 million for Q2 2026 at Alzamend Neuro, down from -$1.7 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of -$688705.0 in Q2 2025 to a low of -$3.4 million in Q4 2024.
• Average Cash from Operations over 5 years is -$2.0 million, with a median of -$1.8 million recorded in 2022.
• Year-over-year, Cash from Operations surged 67.99% in 2024 and plunged 306.17% in 2026.
• Over 5 years, Cash from Operations stood at -$2.3 million in 2022, then soared by 35.44% to -$1.5 million in 2023, then tumbled by 124.66% to -$3.4 million in 2024, then soared by 65.55% to -$1.2 million in 2025, then plunged by 138.79% to -$2.8 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$2.8 million in Q2 2026, -$1.7 million in Q1 2026, and -$1.2 million in Q4 2025.